Evidence labels explain what kind of source is being read.
Dictionary / Evidence method
Human evidence
Evidence from studies involving human participants, kept separate from preclinical and mechanistic evidence.
Evidence methodterm category
0related public pages
editorial navigationdefinition status
draftreview status
114exact evidence rows
82exact source links
0nearby evidence rows
0nearby source links
2do-not-confuse links
0entity links
This page is a dictionary definition and navigation aid. Exact evidence rows below come from approved workbench claims; broader claims and citations live on the related source-backed pages.
Dictionary Reader Map
Use the definition as a doorway, not a conclusion.
Human evidence explains vocabulary used across the cannabinoid encyclopedia. The definition orients the reader; exact rows and related pages carry the source-backed claims.
82 direct sources linked to approved workbench claims. PubMed 37796540
0 nearby evidence rows and 0 nearby source links.
Aliases help readers find the same concept without changing the evidence standard.
Plain-Language Definition
What it means here
Human evidence is used in this encyclopedia as a evidence method term. Evidence from studies involving human participants, kept separate from preclinical and mechanistic evidence.
Evidence-method terms describe how a source should be read. They help separate human trials, observational work, preclinical work, mechanistic studies, and explicit evidence gaps.
Also searched as: clinical evidence, human studies, human study.
Do not confuse with:
Evidence Guardrail
How to read it without overreaching
Use this term to classify the kind of evidence, not to inflate it. A stronger-sounding label still needs source details, study context, outcome measures, and limits.
Evidence Lens
What this term can currently point to
Direct approved claim rows linked to this dictionary term. PubMed 37796540
Distinct source records under those exact rows. PubMed 37796540
Source-backed public pages where this vocabulary is likely useful.
Evidence rows available on those related public pages.
Exact rows are direct evidence links. Use them first, then use related pages to understand the broader research context.
Source Path
How to move from this definition to research
- Read the definition.Use it to understand the vocabulary in plain English.
- Check exact rows.When direct rows exist, open the linked PubMed or DOI record. PubMed 37796540
- Open related pages.Use nearby pages for broader source-backed context.
- Keep the boundary.A method label describes evidence type; it does not make the evidence stronger.
Exact Evidence Rows
Approved source-backed rows linked to this term
114 exact rows
No matching evidence rows.
Evidence Group
Preliminary Human
114 exact rows / 82 sources
Evidence row 2 / evidence context
CBN decreases Nighttime awakenings.
preliminary human / moderate confidence.
A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PubMed 37796540
Evidence class is human evidence.
Evidence row 3 / evidence context
CBN no detected effect on sleep onset latency, wake after sleep onset, or daytime fatigue.
preliminary human / moderate confidence.
A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PubMed 37796540
Evidence class is human evidence.
Evidence row 4 / evidence context
CBN decreases Overall sleep disturbance.
preliminary human / low confidence.
A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Effectiveness and Safety of Melatonin and Three Formulations of Floraworks Proprietary TruCBN for Improving Sleep PubMed 39204082
Evidence class is human evidence.
Evidence row 5 / evidence context
CBN no detected effect on Side effect frequency.
preliminary human / low confidence.
A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Effectiveness and Safety of Melatonin and Three Formulations of Floraworks Proprietary TruCBN for Improving Sleep PubMed 39204082
Evidence class is human evidence.
Evidence row 6 / evidence context
CBN no detected effect on Wake after sleep onset.
preliminary human / moderate confidence.
Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PubMed 41698831
Evidence class is human evidence.
Evidence row 7 / evidence context
CBN decreases Sleep onset latency.
preliminary human / moderate confidence.
Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PubMed 41698831
Evidence class is human evidence.
Evidence row 8 / evidence context
CBN increases Subjective sleep quality.
preliminary human / moderate confidence.
Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PubMed 41698831
Evidence class is human evidence.
Evidence row 9 / evidence context
CBN increases NREM-2 sleep.
preliminary human / moderate confidence.
Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PubMed 41698831
Evidence class is human evidence.
Evidence row 14 / evidence context
CBN decreases Overall sleep disturbance.
preliminary human / moderate confidence.
A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PubMed 37796540
Evidence class is human evidence.
Evidence row 15 / evidence context
CBN associated with Adverse events.
preliminary human / low confidence.
Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PubMed 41698831
Evidence class is human evidence.
Evidence row 16 / evidence context
CBN no detected effect on Sleep onset latency.
preliminary human / moderate confidence.
A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PubMed 37796540
Evidence class is human evidence.
Evidence row 17 / evidence context
CBN no detected effect on Wake after sleep onset.
preliminary human / moderate confidence.
A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PubMed 37796540
Evidence class is human evidence.
Evidence row 18 / evidence context
CBN no detected effect on Daytime fatigue.
preliminary human / moderate confidence.
A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PubMed 37796540
Evidence class is human evidence.
Evidence row 28 / evidence context
CBD studied for Anxiety-related outcomes.
preliminary human / very_low confidence.
Evaluation of the efficacy, safety, and pharmacokinetics of nanodispersible cannabidiol oral solution (150 mg/mL) versus placebo in mild to moderate anxiety subjects: A double blind multicenter randomized clinical trial. PubMed 38797087
Evidence class is human evidence.
Evidence row 29 / evidence context
CBD studied for Anxiety-related outcomes.
preliminary human / very_low confidence.
Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind, and placebo-controlled clinical trial. PubMed 35617670
Evidence class is human evidence.
Evidence row 37 / evidence context
THCV studied for Appetite and metabolic outcomes.
preliminary human / very_low confidence.
Δ9-Tetrahydrocannabivarin (THCV): a commentary on potential therapeutic benefit for the management of obesity and diabetes. PubMed 33526143
Evidence class is human evidence.
Evidence row 46 / evidence context
THCA studied for THCA-specific safety, effect, or mechanism claims.
preliminary human / very_low confidence.
Cannabinoid Content in Cannabis Flowers and Homemade Cannabis-Based Products Used for Therapeutic Purposes in Argentina. PubMed 33998894
Evidence class is human evidence.
Evidence row 57 / evidence context
CBD studied for Anxiety-related outcomes.
preliminary human / very_low confidence.
Cannabidiol for moderate-severe insomnia: a randomized controlled pilot trial of 150 mg of nightly dosing. PubMed 38174873
Evidence class is human evidence.
Evidence row 59 / evidence context
CBD studied for Anxiety-related outcomes.
preliminary human / very_low confidence.
Cannabidiol for Scan-Related Anxiety in Women With Advanced Breast Cancer: A Randomized Clinical Trial. PubMed 39680411
Evidence class is human evidence.
Evidence row 60 / evidence context
CBD studied for Anxiety-related outcomes.
preliminary human / very_low confidence.
Effect of Preoperative Oral Cannabidiol-Rich Cannabis Extract on Anxiety and Postoperative Pain after Endodontic Treatment: A Double-Blind Randomized Clinical Trial. PubMed 39505200
Evidence class is human evidence.
Evidence row 62 / evidence context
CBD studied for Anxiety-related outcomes.
preliminary human / very_low confidence.
Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial. PubMed 39151115
Evidence class is human evidence.
Evidence row 63 / evidence context
CBD studied for Anxiety-related outcomes.
preliminary human / very_low confidence.
Cannabidiol for Treatment-Resistant Anxiety Disorders in Young People: An Open-Label Trial. PubMed 35921510
Evidence class is human evidence.
Evidence row 72 / evidence context
CBC studied for Inflammation-related outcomes.
preliminary human / very_low confidence.
Therapeutic potential of cannabidiol-rich Cannabis sativa to mitigate the severity of inflammation and pain: A pre-clinical study. PubMed 41213439
Evidence class is human evidence.
Evidence row 83 / evidence context
THCV studied for Appetite and metabolic outcomes.
preliminary human / very_low confidence.
Delta9-tetrahydrocannabivarin as a marker for the ingestion of marijuana versus Marinol: results of a clinical study. PubMed 11599601
Evidence class is human evidence.
Evidence row 86 / evidence context
THCA studied for THCA-specific safety, effect, or mechanism claims.
preliminary human / very_low confidence.
Quality and safety of hemp meal as a protein supplement for nonlactating dairy cows. PubMed 37641272
Evidence class is human evidence.
Evidence row 97 / evidence context
Cannabinoids studied for safety, adverse-event, impairment, or formulation-specific concerns.
preliminary human / very_low confidence.
Adverse events associated with medical cannabis reported within a centralized call center. PubMed 42158949
Evidence class is human evidence.
Evidence row 105 / evidence context
Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts.
preliminary human / very_low confidence.
Variation in Hospital Practices Regarding Marijuana Use in Pregnancy and Lactation. PubMed 37729034
Evidence class is human evidence.
Evidence row 107 / evidence context
CBN studied for Sleep.
preliminary human / very_low confidence.
Medical cannabis for treatment of insomnia in adults: A systematic review and meta-analysis. PubMed 42207928
Evidence class is human evidence.
Evidence row 108 / evidence context
CBN studied for Sleep.
preliminary human / very_low confidence.
Effectiveness of a Cannabinoids Supplement on Sleep and Mood in Adults With Subthreshold Insomnia: A Randomized Double-Blind Placebo-Controlled Crossover Pilot Trial. PubMed 39980821
Evidence class is human evidence.
Evidence row 120 / evidence context
CBDV studied for Seizure and neurodevelopmental outcomes.
preliminary human / very_low confidence.
Modulation of striatal functional connectivity differences in adults with and without autism spectrum disorder in a single-dose randomized trial of cannabidivarin. PubMed 34210360
Evidence class is human evidence.
Evidence row 122 / evidence context
CBDV studied for Seizure and neurodevelopmental outcomes.
preliminary human / very_low confidence.
Effects of cannabidivarin (CBDV) on brain excitation and inhibition systems in adults with and without Autism Spectrum Disorder (ASD): a single dose trial during magnetic resonance spectroscopy. PubMed 31748505
Evidence class is human evidence.
Evidence row 149 / evidence context
CBN studied for safety, adverse-event, impairment, or formulation-specific concerns.
preliminary human / very_low confidence.
Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PubMed 41698831
Evidence class is human evidence.
Evidence row 155 / evidence context
Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns.
preliminary human / very_low confidence.
Unintentional ingestion of putative delta-8 tetrahydrocannabinol by two youth requiring critical care: a case report. PubMed 36941718
Evidence class is human evidence.
Evidence row 156 / evidence context
Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns.
preliminary human / very_low confidence.
Using Large Language Models to Support Content Analysis: A Case Study of ChatGPT for Adverse Event Detection. PubMed 38696245
Evidence class is human evidence.
Evidence row 159 / evidence context
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns.
preliminary human / very_low confidence.
A randomized, double-blind, placebo-controlled, repeated-dose pilot study of the safety, tolerability, and preliminary effects of a cannabidiol (CBD)- and cannabigerol (CBG)-based beverage powder to support recovery from delayed onset muscle soreness (DOMS). PubMed 37947792
Evidence class is human evidence.
Evidence row 162 / evidence context
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns.
preliminary human / very_low confidence.
Safety study of cannabidiol products in healthy dogs. PubMed 38496308
Evidence class is human evidence.
Evidence row 163 / evidence context
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns.
preliminary human / very_low confidence.
Transcriptomic comparison on the mechanism of action of four major constituent cannabinoids in hemp extract. PubMed 42057192
Evidence class is human evidence.
Evidence row 169 / evidence context
CBC studied for safety, adverse-event, impairment, or formulation-specific concerns.
preliminary human / very_low confidence.
The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled Trial. PubMed 37162192
Evidence class is human evidence.
Evidence row 183 / evidence context
THC studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts.
preliminary human / very_low confidence.
Development and validation of the Cannabis Exposure in Pregnancy Tool (CEPT): a mixed methods study. PubMed 38627667
Evidence class is human evidence.
Evidence row 186 / evidence context
CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts.
preliminary human / very_low confidence.
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. PubMed 26724101
Evidence class is human evidence.
Evidence row 187 / evidence context
Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts.
preliminary human / very_low confidence.
Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. PubMed 25479151
Evidence class is human evidence.
Evidence row 221 / evidence context
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
preliminary human / very_low confidence.
The contribution of addictovigilance data to the French medical cannabis experimentation. PubMed 39547825
Evidence class is human evidence.
Evidence row 227 / evidence context
CBD studied for safety, risk, adverse-event, or formulation-specific concerns.
preliminary human / very_low confidence.
A Phase-2 Open-Label Trial of Cannabidiol to Treat Core and Associated Symptoms of Autism in Children and Adolescents Without Intellectual Disability. PubMed 42204954
Evidence class is human evidence.
Evidence row 233 / evidence context
THC studied for Cannabinoids and nausea/vomiting research outcomes.
preliminary human / very_low confidence.
Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial. PubMed 39151115
Evidence class is human evidence.
Evidence row 238 / evidence context
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
preliminary human / very_low confidence.
Adverse Effects of Recreational and Medical Cannabis. PubMed 33897066
Evidence class is human evidence.
Evidence row 299 / evidence context
Endocannabinoids studied for Endocannabinoids and endocannabinoid-like lipids research topics.
preliminary human / very_low confidence.
Liquid Chromatography-Tandem Mass Spectrometry Method for Simultaneous Quantification of Four Endocannabinoids and Endocannabinoid-Like Substances in Plasma: Application in an HIV-Hepatitis C Virus Coinfected Population. PubMed 41035123
Evidence class is human evidence.
Evidence row 311 / evidence context
THC modulates endocannabinoid enzyme activity or metabolic mechanisms.
preliminary human / very_low confidence.
Impact of tetrahydrocannabinol on the endocannabinoid 2-arachidonoylglycerol metabolism: ABHD6 and ABHD12 as novel players in human placenta. PubMed 32829065
Evidence class is human evidence.
Evidence row 314 / evidence context
Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms.
preliminary human / very_low confidence.
Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12). PubMed 22969151
Evidence class is human evidence.
Evidence row 321 / evidence context
CBD studied for safety, risk, adverse-event, or formulation-specific concerns.
preliminary human / very_low confidence.
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. PubMed 26724101
Evidence class is human evidence.
Evidence row 323 / evidence context
CBD studied for safety, risk, adverse-event, or formulation-specific concerns.
preliminary human / very_low confidence.
Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. PubMed 29768152
Evidence class is human evidence.
Evidence row 324 / evidence context
CBD studied for safety, risk, adverse-event, or formulation-specific concerns.
preliminary human / very_low confidence.
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. PubMed 28538134
Evidence class is human evidence.
Evidence row 334 / evidence context
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
preliminary human / very_low confidence.
Potency Analysis of Medical Marijuana Products from New York State. PubMed 31559335
Evidence class is human evidence.
Evidence row 338 / evidence context
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
preliminary human / very_low confidence.
Cannabinoids in dermatology: a scoping review. PubMed 30142706
Evidence class is human evidence.
Evidence row 350 / evidence context
Delta-8 THC studied for safety, risk, adverse-event, or formulation-specific concerns.
preliminary human / very_low confidence.
Using Transformer-Based Topic Modeling to Examine Discussions of Delta-8 Tetrahydrocannabinol: Content Analysis. PubMed 38127427
Evidence class is human evidence.
Evidence row 351 / evidence context
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
preliminary human / very_low confidence.
Derivation of a health-based guidance value for Δ8-tetrahydrocannabinol (Δ8-THC) and its occurrence in food. PubMed 41262681
Evidence class is human evidence.
Evidence row 354 / evidence context
HHC studied for safety, risk, adverse-event, or formulation-specific concerns.
preliminary human / very_low confidence.
[Not Available]. PubMed 39323250
Evidence class is human evidence.
Evidence row 365 / evidence context
CBD modulates endocannabinoid enzyme activity or metabolic mechanisms.
preliminary human / very_low confidence.
Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. PubMed 29768152
Evidence class is human evidence.
Evidence row 366 / evidence context
CBD modulates endocannabinoid enzyme activity or metabolic mechanisms.
preliminary human / very_low confidence.
Cannabidiol and Liver Enzyme Level Elevations in Healthy Adults: A Randomized Clinical Trial. PubMed 40622698
Evidence class is human evidence.
Evidence row 368 / evidence context
CBD modulates endocannabinoid enzyme activity or metabolic mechanisms.
preliminary human / very_low confidence.
Observed Impact of Long-Term Consumption of Oral Cannabidiol on Liver Function in Healthy Adults. PubMed 34918948
Evidence class is human evidence.
Evidence row 382 / evidence context
CBD studied for Seizure and neurodevelopmental outcomes.
preliminary human / very_low confidence.
Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial. PubMed 33346789
Evidence class is human evidence.
Evidence row 387 / evidence context
CBD studied for Seizure and neurodevelopmental outcomes.
preliminary human / very_low confidence.
Real-world evidence on the use of cannabidiol for the treatment of drug resistant epilepsy not related to Lennox-Gastaut syndrome, Dravet syndrome or Tuberous Sclerosis Complex. PubMed 37769547
Evidence class is human evidence.
Evidence row 388 / evidence context
CBD studied for Seizure and neurodevelopmental outcomes.
preliminary human / very_low confidence.
Retrospective Multicenter Chart Review Study of Adjunctive Cannabidiol for Seizures Associated with Lennox-Gastaut Syndrome, Dravet Syndrome and Tuberous Sclerosis Complex. PubMed 40650804
Evidence class is human evidence.
Evidence row 395 / evidence context
CBD studied for Pain-related outcomes.
preliminary human / very_low confidence.
Cannabis-Based Medicine for Neuropathic Pain and Spasticity-A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial. PubMed 37630995
Evidence class is human evidence.
Evidence row 396 / evidence context
CBD studied for Pain-related outcomes.
preliminary human / very_low confidence.
High-dose cannabidiol for chronic neuropathic pain associated with spinal cord injury: a randomised clinical trial. PubMed 42256679
Evidence class is human evidence.
Evidence row 398 / evidence context
CBD studied for Pain-related outcomes.
preliminary human / very_low confidence.
The Effectiveness of Topical Cannabidiol Oil in Symptomatic Relief of Peripheral Neuropathy of the Lower Extremities. PubMed 31793418
Evidence class is human evidence.
Evidence row 401 / evidence context
CBD studied for Pain-related outcomes.
preliminary human / very_low confidence.
Oral capsules of tetra-hydro-cannabinol (THC), cannabidiol (CBD) and their combination in peripheral neuropathic pain treatment. PubMed 36571471
Evidence class is human evidence.
Evidence row 402 / evidence context
CBD studied for Pain-related outcomes.
preliminary human / very_low confidence.
Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. PubMed 18035205
Evidence class is human evidence.
Evidence row 403 / evidence context
CBD studied for Sleep.
preliminary human / very_low confidence.
Cannabidiol for moderate-severe insomnia: a randomized controlled pilot trial of 150 mg of nightly dosing. PubMed 38174873
Evidence class is human evidence.
Evidence row 404 / evidence context
CBD studied for Sleep.
preliminary human / very_low confidence.
Effectiveness of a Cannabinoids Supplement on Sleep and Mood in Adults With Subthreshold Insomnia: A Randomized Double-Blind Placebo-Controlled Crossover Pilot Trial. PubMed 39980821
Evidence class is human evidence.
Evidence row 405 / evidence context
CBD studied for Sleep.
preliminary human / very_low confidence.
Medicinal cannabis improves sleep in adults with insomnia: a randomised double-blind placebo-controlled crossover study. PubMed 36539991
Evidence class is human evidence.
Evidence row 406 / evidence context
CBD studied for Sleep.
preliminary human / very_low confidence.
Effects of a cannabidiol/terpene formulation on sleep in individuals with insomnia: a double-blind, placebo-controlled, randomized, crossover study. PubMed 39167421
Evidence class is human evidence.
Evidence row 407 / evidence context
CBD studied for Sleep.
preliminary human / very_low confidence.
The effect of nightly use of 150 mg cannabidiol on daytime neurocognitive performance in primary insomnia: a randomized controlled pilot trial. PubMed 39153080
Evidence class is human evidence.
Evidence row 409 / evidence context
CBD studied for Sleep.
preliminary human / very_low confidence.
Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial. PubMed 40631525
Evidence class is human evidence.
Evidence row 414 / evidence context
CBD studied for Sleep.
preliminary human / very_low confidence.
Evaluating possible 'next day' impairment in insomnia patients administered an oral medicinal cannabis product by night: a pilot randomized controlled trial. PubMed 38758300
Evidence class is human evidence.
Evidence row 416 / evidence context
CBD studied for Seizure and neurodevelopmental outcomes.
preliminary human / very_low confidence.
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. PubMed 26724101
Evidence class is human evidence.
Evidence row 417 / evidence context
CBD studied for Seizure and neurodevelopmental outcomes.
preliminary human / very_low confidence.
Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. PubMed 29395273
Evidence class is human evidence.
Evidence row 419 / evidence context
CBD studied for Seizure and neurodevelopmental outcomes.
preliminary human / very_low confidence.
Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. PubMed 29768152
Evidence class is human evidence.
Evidence row 420 / evidence context
CBD studied for Seizure and neurodevelopmental outcomes.
preliminary human / very_low confidence.
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. PubMed 28538134
Evidence class is human evidence.
Evidence row 432 / evidence context
CBD studied for Pain-related outcomes.
preliminary human / very_low confidence.
Ingestion of a THC-Rich Cannabis Oil in People with Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. PubMed 33118602
Evidence class is human evidence.
Evidence row 433 / evidence context
CBD studied for Pain-related outcomes.
preliminary human / very_low confidence.
Cannabidiol-Enriched Extract Oil for Postoperative Management of Chronic Pelvic Pain Secondary to Endometriosis: A Randomized Clinical Trial-DREAMLAND Study. PubMed 42261989
Evidence class is human evidence.
Evidence row 450 / evidence context
THC studied for Cardiovascular risk.
preliminary human / very_low confidence.
The effects of combinations of intranasal cocaine, smoked marijuana, and task performance on heart rate and blood pressure. PubMed 2162543
Evidence class is human evidence.
Evidence row 451 / evidence context
THC studied for Cardiovascular risk.
preliminary human / very_low confidence.
Cumulative Effects of Cannabis Oils on Body Temperature, Electrocardiography, Heart Rate Variability, Blood Pressure, and Respiratory Function in Telemetered Dogs. PubMed 42131827
Evidence class is human evidence.
Evidence row 462 / evidence context
THC studied for Cognition and memory.
preliminary human / very_low confidence.
Δ9-Tetrahydrocannabinol (THC) impairs visual working memory performance: a randomized crossover trial. PubMed 32386395
Evidence class is human evidence.
Evidence row 468 / evidence context
THC studied for Cognition and memory.
preliminary human / very_low confidence.
The Individual and Interactive Effects of Alpha-Pinene and Delta-9-Tetrahydrocannabinol in Healthy Adults. PubMed 40734690
Evidence class is human evidence.
Evidence row 469 / evidence context
THC studied for Cognition and memory.
preliminary human / very_low confidence.
Cognitive and subjective dose-response effects of acute oral Delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users. PubMed 12373420
Evidence class is human evidence.
Evidence row 474 / evidence context
THC studied for Pain-related outcomes.
preliminary human / very_low confidence.
Ingestion of a THC-Rich Cannabis Oil in People with Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. PubMed 33118602
Evidence class is human evidence.
Evidence row 482 / evidence context
THC studied for Nausea and vomiting.
preliminary human / very_low confidence.
Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial. PubMed 39151115
Evidence class is human evidence.
Evidence row 492 / evidence context
THC studied for Appetite and metabolic outcomes.
preliminary human / very_low confidence.
Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. PubMed 16849753
Evidence class is human evidence.
Evidence row 497 / evidence context
THC studied for Appetite and metabolic outcomes.
preliminary human / very_low confidence.
The Effects of Dosage-Controlled Cannabis Capsules on Cancer-Related Cachexia and Anorexia Syndrome in Advanced Cancer Patients: Pilot Study. PubMed 31595793
Evidence class is human evidence.
Evidence row 499 / evidence context
THC studied for Sleep.
preliminary human / very_low confidence.
Medicinal cannabis improves sleep in adults with insomnia: a randomised double-blind placebo-controlled crossover study. PubMed 36539991
Evidence class is human evidence.
Evidence row 500 / evidence context
THC studied for Sleep.
preliminary human / very_low confidence.
Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial. PubMed 40631525
Evidence class is human evidence.
Evidence row 503 / evidence context
THC studied for Sleep.
preliminary human / very_low confidence.
Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) for chronic insomnia disorder ('CANSLEEP' trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial. PubMed 32430450
Evidence class is human evidence.
Evidence row 505 / evidence context
THC studied for Sleep.
preliminary human / very_low confidence.
Cannabis: are there any benefits? PubMed 33215831
Evidence class is human evidence.
Evidence row 508 / evidence context
CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns.
preliminary human / very_low confidence.
A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PubMed 37796540
Evidence class is human evidence.
Evidence row 509 / evidence context
CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns.
preliminary human / very_low confidence.
Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PubMed 41698831
Evidence class is human evidence.
Evidence row 510 / evidence context
CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns.
preliminary human / very_low confidence.
Effectiveness of a Cannabinoids Supplement on Sleep and Mood in Adults With Subthreshold Insomnia: A Randomized Double-Blind Placebo-Controlled Crossover Pilot Trial. PubMed 39980821
Evidence class is human evidence.
Evidence row 512 / evidence context
CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns.
preliminary human / very_low confidence.
The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled Trial. PubMed 37162192
Evidence class is human evidence.
Evidence row 538 / evidence context
CBN studied for Pain-related outcomes.
preliminary human / very_low confidence.
Nav1.8, an analgesic target for nonpsychotomimetic phytocannabinoids. PubMed 39835903
Evidence class is human evidence.
Evidence row 544 / evidence context
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
preliminary human / very_low confidence.
A randomized, double-blind, placebo-controlled, repeated-dose pilot study of the safety, tolerability, and preliminary effects of a cannabidiol (CBD)- and cannabigerol (CBG)-based beverage powder to support recovery from delayed onset muscle soreness (DOMS). PubMed 37947792
Evidence class is human evidence.
Evidence row 546 / evidence context
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
preliminary human / very_low confidence.
Safety study of cannabidiol products in healthy dogs. PubMed 38496308
Evidence class is human evidence.
Evidence row 612 / evidence context
CBG studied for Skin and inflammatory dermatology.
preliminary human / very_low confidence.
Evaluation of Biophysical Parameters of the Skin of Patients With Atopic Dermatitis After Application of an Ointment Containing 30% Cannabidiol and 5% Cannabigerol. PubMed 40124934
Evidence class is human evidence.
Evidence row 629 / evidence context
CBG studied for Appetite and metabolic outcomes.
preliminary human / very_low confidence.
Survey of Patients Employing Cannabigerol-Predominant Cannabis Preparations: Perceived Medical Effects, Adverse Events, and Withdrawal Symptoms. PubMed 34569849
Evidence class is human evidence.
Evidence row 632 / evidence context
CBG studied for Appetite and metabolic outcomes.
preliminary human / very_low confidence.
Urinary cannabinoid mass spectrometry profiles differentiate dronabinol from cannabis use. PubMed 32795544
Evidence class is human evidence.
Evidence row 637 / evidence context
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
preliminary human / very_low confidence.
Transcriptomic comparison on the mechanism of action of four major constituent cannabinoids in hemp extract. PubMed 42057192
Evidence class is human evidence.
Evidence row 641 / evidence context
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
preliminary human / very_low confidence.
The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled Trial. PubMed 37162192
Evidence class is human evidence.
Evidence row 687 / evidence context
CBC studied for Pain-related outcomes.
preliminary human / very_low confidence.
Therapeutic potential of cannabidiol-rich Cannabis sativa to mitigate the severity of inflammation and pain: A pre-clinical study. PubMed 41213439
Evidence class is human evidence.
Evidence row 717 / evidence context
CBC studied for Skin and inflammatory dermatology.
preliminary human / very_low confidence.
Broad-spectrum bactericidal synergy of silver-cannabichromene-cannabigerol triple combinations against healthcare-associated pathogens. PubMed 41983582
Evidence class is human evidence.
Evidence row 745 / evidence context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
preliminary human / very_low confidence.
A Two-Phase, Dose-Ranging, Placebo-Controlled Study of the Safety and Preliminary Test of Acute Effects of Oral Δ8-Tetrahydrocannabivarin in Healthy Participants. PubMed 37721990
Evidence class is human evidence.
Evidence row 793 / evidence context
THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes.
preliminary human / very_low confidence.
The CB1 Neutral Antagonist Tetrahydrocannabivarin Reduces Default Mode Network and Increases Executive Control Network Resting State Functional Connectivity in Healthy Volunteers. PubMed 26362774
Evidence class is human evidence.
Evidence row 804 / evidence context
THCV studied for Pain-related outcomes.
preliminary human / very_low confidence.
Quantification of Eight Cannabinoids Including Cannabidiol in Human Urine Via Liquid Chromatography Tandem Mass Spectrometry. PubMed 30350275
Evidence class is human evidence.
Evidence row 968 / evidence context
Endocannabinoids modulates GPR119.
preliminary human / very_low confidence.
Members of the endocannabinoid system are distinctly regulated in inflammatory bowel disease and colorectal cancer. PubMed 30787385
Evidence class is human evidence.
Evidence row 1173 / evidence context
LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms.
preliminary human / very_low confidence.
Oral ibuprofen differentially affects plasma and sweat lipid mediator profiles in healthy adult males. PubMed 29778785
Evidence class is human evidence.
Evidence row 1175 / evidence context
LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms.
preliminary human / very_low confidence.
Antipsychotic Medication Influences the Discriminative Value of Acylethanolamides as Biomarkers of Substance Use Disorder. PubMed 37298321
Evidence class is human evidence.
Evidence row 1192 / evidence context
SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms.
preliminary human / very_low confidence.
Serum levels of endocannabinoids and related lipids in painful vs painless diabetic neuropathy: results from the Pain in Neuropathy Study. PubMed 37578507
Evidence class is human evidence.
Source-Backed Connections
Related pages in the current encyclopedia
No source-backed public page is linked to this term in the current launch set yet. Start with the evidence method, then add sources as the term page matures.
Nearby Terms